Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 156

1.

Similar HbA1c reduction and hypoglycaemia with variable- vs fixed-time dosing of basal insulin peglispro in type 1 diabetes: IMAGINE 7 study.

Garg S, Selam JL, Bhargava A, Schloot N, Luo J, Zhang Q, Jacobson JG, Hoogwerf BJ.

Diabetes Obes Metab. 2016 Oct;18 Suppl 2:43-49. doi: 10.1111/dom.12740.

PMID:
27393722
2.

Basal insulin peglispro versus insulin glargine in insulin-naïve type 2 diabetes: IMAGINE 2 randomized trial.

Davies MJ, Russell-Jones D, Selam JL, Bailey TS, Kerényi Z, Luo J, Bue-Valleskey J, Iványi T, Hartman ML, Jacobson JG, Jacober SJ; IMAGINE 2 Study Investigators.

Diabetes Obes Metab. 2016 Nov;18(11):1055-1064. doi: 10.1111/dom.12712. Epub 2016 Aug 12.

3.

Skin collagen pentosidine and fluorescence in diabetes were predictors of retinopathy progression and creatininemia increase already 6years after punch-biopsy.

Sternberg M, M'bemba J, Urios P, Borsos AM, Selam JL, Peyroux J, Slama G.

Clin Biochem. 2016 Feb;49(3):225-31. doi: 10.1016/j.clinbiochem.2015.10.011. Epub 2015 Oct 24.

PMID:
26506116
4.

Evolution of diabetes insulin delivery devices.

Selam JL.

J Diabetes Sci Technol. 2010 May 1;4(3):505-13. Review.

5.

Lacosamide in painful diabetic neuropathy: an 18-week double-blind placebo-controlled trial.

Shaibani A, Fares S, Selam JL, Arslanian A, Simpson J, Sen D, Bongardt S.

J Pain. 2009 Aug;10(8):818-28. doi: 10.1016/j.jpain.2009.01.322. Epub 2009 May 5.

PMID:
19409861
6.

Comparison of a multiple daily insulin injection regimen (basal once-daily glargine plus mealtime lispro) and continuous subcutaneous insulin infusion (lispro) in type 1 diabetes: a randomized open parallel multicenter study.

Bolli GB, Kerr D, Thomas R, Torlone E, Sola-Gazagnes A, Vitacolonna E, Selam JL, Home PD.

Diabetes Care. 2009 Jul;32(7):1170-6. doi: 10.2337/dc08-1874. Epub 2009 Apr 23. Erratum in: Diabetes Care. 2009 Oct;32(10):1944.

7.

Basal-bolus therapy with insulin detemir using the 303 algorithm in the US PREDICTIVE 303 trial.

Selam JL, Meneghini LF.

Adv Ther. 2009 Feb;26(2):194-207. doi: 10.1007/s12325-009-0007-8. Epub 2009 Mar 2.

PMID:
19259629
8.

Cyclic relationships between diabetic nephropathy and cardiovascular risk factors.

Charles MA, Selam JL.

Metab Syndr Relat Disord. 2005 Fall;3(3):203-12. doi: 10.1089/met.2005.3.203.

PMID:
18370788
9.

Inhaled insulin: promises and concerns.

Sélam JL.

J Diabetes Sci Technol. 2008 Mar;2(2):311-5.

12.

Continuous intraperitoneal insulin infusion does not increase the risk of organ-specific autoimmune disease in type 1 diabetic patients: results of a multicentric, comparative study.

Dufaitre-Patouraux L, Riveline JP, Renard E, Melki V, Belicar-Schaepelynck P, Selam JL, Guerci B, Millot L, Brun JM, Fermon C, Catargi B, Gin H, Jeandidier N, Lejeune PJ, Lassmann-Vague V.

Diabetes Metab. 2006 Nov;32(5 Pt 1):427-32.

PMID:
17110897
13.

[Inhaled insulin, new perspective for insulin therapy].

Radermecker RP, Sélam JL.

Rev Med Liege. 2005 May-Jun;60(5-6):355-60. Review. French.

14.
15.
16.
17.

Benefits and risks of solitary islet transplantation for type 1 diabetes using steroid-sparing immunosuppression.

Charles MA, Selam JL.

Diabetes Care. 2004 May;27(5):1249-50; author reply 1250-1. No abstract available.

PMID:
15111573
18.

Combined improvements in implantable pump technology and insulin stability allow safe and effective long term intraperitoneal insulin delivery in type 1 diabetic patients: the EVADIAC experience.

Gin H, Renard E, Melki V, Boivin S, Schaepelynck-Bélicar P, Guerci B, Selam JL, Brun JM, Riveline JP, Estour B, Catargi B; EVADIAC Study Group.

Diabetes Metab. 2003 Dec;29(6):602-7.

PMID:
14707889
19.

Effects of dipeptide administration on hypoglycaemic counterregulation in type 1 diabetes.

M'bemba J, Cynober L, de Bandt P, Taverna M, Chevalier A, Bardin C, Slama G, Selam JL.

Diabetes Metab. 2003 Sep;29(4 Pt 1):412-7.

PMID:
14526269
20.

Successful treatment of insulin allergy in a type 1 diabetic patient by means of constant subcutaneous pump infusion of insulin.

Sola-Gazagnes A, Pecquet C, Radermecker R, Piétri L, Elgrably F, Slama G, Sélam JL.

Diabetes Care. 2003 Oct;26(10):2961-2. No abstract available.

PMID:
14514615
21.

Inhaled insulin for the treatment of diabetes: projects and devices.

Selam JL.

Expert Opin Pharmacother. 2003 Aug;4(8):1373-7. Review.

PMID:
12877644
22.

[Type I diabetes in adults and children].

Selam JL.

Rev Prat. 2003 May 1;53(9):995-1005. French. No abstract available.

PMID:
12816040
23.

Accuracy of the continuous glucose monitoring system in inpatient and outpatient conditions.

Djakouré-Platonoff C, Radermercker R, Reach G, Slama G, Selam JI.

Diabetes Metab. 2003 Apr;29(2 Pt 1):159-62. doi: 10.1016/S1262-3636(07)70023-X.

24.

[How I explore...glycemic kinetics by continuous glucose monitoring].

Radermecker RP, Magis D, Sélam JL, Scheen AJ.

Rev Med Liege. 2003 Mar;58(3):164-7. Review. French.

25.
26.

eNOS4 polymorphism of the endothelial nitric oxide synthase predicts risk for severe diabetic retinopathy.

Taverna MJ, Sola A, Guyot-Argenton C, Pacher N, Bruzzo F, Chevalier A, Slama G, Reach G, Selam JL.

Diabet Med. 2002 Mar;19(3):240-5.

PMID:
11918626
27.

Taq I polymorphism of the vitamin D receptor and risk of severe diabetic retinopathy.

Taverna MJ, Sola A, Guyot-Argenton C, Pacher N, Bruzzo F, Slama G, Reach G, Selam JL.

Diabetologia. 2002 Mar;45(3):436-42.

PMID:
11914750
28.

[Inhaled insulin: clinical results in type 2 diabetic patients].

Selam JL.

Diabetes Metab. 2001 Nov;27(5 Pt 3):S28-32. Review. French.

PMID:
11910977
29.

Sildenafil citrate for the treatment of erectile dysfunction in men with Type II diabetes mellitus.

Boulton AJ, Selam JL, Sweeney M, Ziegler D.

Diabetologia. 2001 Oct;44(10):1296-301.

PMID:
11692178
30.

Efficacy and tolerance of intranasal insulin administered during 4 months in severely hyperglycaemic Type 2 diabetic patients with oral drug failure: a cross-over study.

Lalej-Bennis D, Boillot J, Bardin C, Zirinis P, Coste A, Escudier E, Chast F, Peynegre R, Selam JL, Slama G.

Diabet Med. 2001 Aug;18(8):614-8.

PMID:
11553197
31.

Beta-cell function evaluated by HOMA as a predictor of secondary sulphonylurea failure in Type 2 diabetes.

Taverna MJ, Pacher N, Bruzzo F, Slama G, Selam JL.

Diabet Med. 2001 Jul;18(7):584-8.

PMID:
11553190
32.

External and implantable insulin pumps: current place in the treatment of diabetes.

Selam JL.

Exp Clin Endocrinol Diabetes. 2001;109 Suppl 2:S333-40. Review.

PMID:
11460581
33.

Six month administration of gelified intranasal insulin in 16 type 1 diabetic patients under multiple injections: efficacy vs subcutaneous injections and local tolerance.

Lalej-Bennis D, Boillot J, Bardin C, Zirinis P, Coste A, Escudier E, Chast F, Peynegre R, Slama G, Selam JL.

Diabetes Metab. 2001 Jun;27(3):372-7.

PMID:
11431603
34.

[Considerations on delocalized HbA1c assays].

Bordas-Fonfrède M, Sélam J, Goudable J, Thivolet C, Vialettes B, Chapelle J, Drouin P, Hue G, Lévy-Marchal C, Slama G, Gillery P.

Diabetes Metab. 2000 Dec;26(6):508-12. Review. French.

PMID:
11173724
35.

[How to prescribing Viagra in practice...].

Lalej-Bennis D, Sellam R, Selam JL, Slama G.

Diabetes Metab. 2000 Nov;26(5):416-20. Review. French.

PMID:
11119023
36.

[Hemoglobin A1C determination and hemoglobinopathies: problems and strategies].

Gillery P, Hue G, Bordas-Fonfrède M, Chapelle JP, Drouin P, Lévy-Marchal C, Périer C, Sélam JL, Slama G, Thivolet C, Vialettes B.

Ann Biol Clin (Paris). 2000 Jul-Aug;58(4):425-9. Review. French.

37.

[How to measure glycemic instability?].

Selam JL.

Diabetes Metab. 2000 Apr;26(2):148-51. French.

PMID:
10804331
38.
39.

Insufficient adaptation of hypoglycaemic threshold for cognitive impairment in tightly controlled type 1 diabetes.

Taverna MJ, M'Bemba J, Sola A, Chevalier A, Slama G, Selam JL.

Diabetes Metab. 2000 Feb;26(1):58-64.

PMID:
10705105
40.

[Drug therapy of type 2 diabetes with 1.26g/l fasting blood glucose (see above)].

Slama G, Selam JL, Elgrably F, Reach G.

Diabetes Metab. 1999 Nov;25(5):436-40. French. No abstract available.

PMID:
10592869
41.

HBA1c: clinical and biological agreement for standardization of assay methods. Report by the experts of ALFEDIAM (Association de Langue Française pour lEtude du Diabète et des Maladies Métabolique) and SFBC (Société Française de Biologie Clinique).

Gillery P, Bordas-Fonfrède M, Chapelle JP, Drouin P, Hue G, Lévy-Marchal C, Périer C, Sélam JL, Slama G, Thivolet C, Vialettes B.

Diabetes Metab. 1999 Sep;25(3):283-7. French.

PMID:
10499200
42.

Implantable insulin pumps.

Selam JL.

Lancet. 1999 Jul 17;354(9174):178-9. No abstract available.

PMID:
10421296
43.

[Reevaluation of hypoglycemic risk in the course of intensive insulin therapy].

Selam JL.

Journ Annu Diabetol Hotel Dieu. 1998:257-80. Review. French. No abstract available.

PMID:
9773626
44.

[Lispro (humalog) insulin in practice].

Selam JL, Slama G.

Diabetes Metab. 1998 Jun;24(3):272-5. Review. French. No abstract available.

PMID:
9690063
45.

[A new strategy for education and management of insulin-dependent diabetics].

Traynard PY, Elgrably F, Selam JL, Slama G.

Diabetes Metab. 1998 Apr;24(2):173-7. Review. French. No abstract available.

PMID:
9592645
46.

[Cognitive risk from recurrent hypoglycemia in the diabetic].

Selam JL.

Diabetes Metab. 1998 Apr;24(2):167-72. Review. French. No abstract available.

PMID:
9592644
47.

Lispro insulin is suitable for external pumps but not for implantable pumps.

Demirdjian S, Bardin C, Savin S, Zirinis P, Chast F, Slama G, Sélam JL.

Diabetes Care. 1998 May;21(5):867-8. No abstract available.

PMID:
9589258
48.

Extreme insulin resistance: clinical management by external subcutaneous insulin infusion.

Lalej-Bennis D, Selam JL, Fluteau-Nadler S, M'Bemba J, Reach G, Sorel G, Bardin C, Zirinis P, Chast F, Elgrably F, Slama G.

Diabetes Metab. 1997 Dec;23(6):533-6.

PMID:
9496561
49.

[Pharmacokinetics of hypoglycemic sulfonamides: Ozidia, a new concept].

Selam JL.

Diabetes Metab. 1997 Nov;23 Suppl 4:39-43. Review. French.

PMID:
9463023
50.

[From the concept of fast acting analogs to the properties of the insulin Lispro].

Selam JL.

Diabetes Metab. 1997 Sep;23 Suppl 3:45-9. Review. French.

PMID:
9410552

Supplemental Content

Support Center